RedHill Biopharma Announces Conclusion Of End-of-Phase II Meeting With FDA On BEKINDA; Co. Plans To Finalize Design Of Two Phase 3 Studies To Accelerate Partnership Discussions, Including US Co-Promotion Opportunities
Benzinga Newsdesk